Sulfonylureas (diabetes).

What they do

Sulfonylureas lower blood glucose by stimulating insulin secretion from pancreatic β-cells. They bind to the SUR1 subunit of the ATP-sensitive potassium channel (KATP) on the β-cell membrane, closing it. The membrane depolarises, voltage-gated calcium channels open, and insulin is released. The effect is independent of blood glucose level — which is why hypoglycemia is the most important adverse effect.

Common indications are type 2 diabetes mellitus, often as add-on to metformin when monotherapy is insufficient and other classes are not chosen. Sulfonylureas are inexpensive and effective at lowering A1c, but they have largely lost first-line position in modern guidelines to other classes (notably SGLT2 inhibitors and GLP-1 receptor agonists) because of comparative cardiovascular and weight outcomes.

Hypoglycemia and other effects

The dominant adverse effect is hypoglycemia, which can be severe and prolonged, particularly with the longer-acting agents (glyburide notably) and in older patients, those with kidney impairment, those eating less than usual, those drinking alcohol, or those on interacting drugs. Weight gain is common. Less common effects include rashes, photosensitivity, hyponatremia (notably with chlorpropamide, an older agent), and rare hematologic reactions. Glyburide is generally avoided in older adults in many practice guidelines because of the hypoglycemia profile.

The sulfa allergy question

Sulfonylureas contain a sulfonamide moiety as part of their pharmacophore. They do not carry an N4 arylamine and are not antibacterial. In published data, cross-reactivity with sulfa antibiotic allergy is low. Most clinicians are comfortable prescribing sulfonylureas in patients with a documented mild sulfa antibiotic allergy. Decisions in patients with severe past reactions are individualised.

The first-generation sulfonylureas (tolbutamide, chlorpropamide, tolazamide, acetohexamide) are largely historical. The second-generation drugs in current use are structurally distinct enough from sulfa antibiotics that the cross-reactivity question is essentially the same as for the diuretics — low. The structural reasoning is on antibiotic vs non-antibiotic sulfonamides.

Where sulfonylureas sit today

Modern type 2 diabetes guidelines from major bodies have shifted recommendations toward agents with cardiovascular and renal outcome benefits — particularly SGLT2 inhibitors (empagliflozin, dapagliflozin, others) and GLP-1 receptor agonists (semaglutide, liraglutide, others). Sulfonylureas remain important where cost matters, where these newer classes are not available, where add-on therapy is needed, or where particular patient factors apply. They are still widely prescribed worldwide.

A side note on glinides

The meglitinides (repaglinide, nateglinide) act on the same KATP channel through a related mechanism. They are not sulfonamides — they lack the –SO2NH2 group entirely — and are not part of the sulfa cross-reactivity question. They are mentioned here only because they are sometimes confused with sulfonylureas in clinical reasoning. Their adverse effect profile is broadly similar in kind (hypoglycemia, weight effects) but with shorter duration of action.

See also

• Cross-reactivityThe general picture for non-antibiotic sulfonamides.→
• Antibiotic vs non-antibiotic sulfonamidesThe structural reason cross-reactivity is low.→
• Common cross-reactivity questionsThe recurring patient queries.→
• Sulfa allergy: overviewWhat the label usually means.→